Fairvalue-Calculator Fairvalue-Calculator
EN DE

Pharmosa Biopharm Inc (6875) Fair Value & Analysis

Healthcare · TW · Market cap 4.5B TWD

Price36.70 TWD
Fair Value36.18 TWD
Upside-1.4%
Quality91/100
Evidence: Low Range 27.13 TWD – 45.22 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Pharmosa Biopharm Inc (6875) currently trades at 36.70 TWD, while our model-based Fair Value estimate is 36.18 TWD — implying the stock looks roughly 1.4% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharmosa Biopharm Inc. was founded in 2000 and is headquartered in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Pharmosa Biopharm Inc (6875) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 36.18 TWD versus a price of 36.70 TWD — about −1% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6875?
Our 21-model fair value for Pharmosa Biopharm Inc is 36.18 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 36.70 TWD.
What is the quality score of 6875?
Pharmosa Biopharm Inc has a Quality Score of 91/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.